Glimepiride

Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl® by Aventis. Description Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.

Mechanism of Action Glimepiride distinctly lower the blood glucose level by both defects of NIDDM, by stimulating pancreatic beta cells to produce more insulin and induced increased activity of peripheral insulin intra cellular receptor.

Clinical Pharmacology With Glimepiride GI absorption is complete with no interference of meals. Significant absorption of glimepiride was seen within one hour, and distributed through out the body, bound to the plasma protein to an extended of 99.5% and it is metabolised by oxidative biotransformation and 60% is excreted in the urine, and remaining is excreted in the faeces.

Indications Type 2 diabetes (or) NIDDM

Dosage There is no fixed dosage regimen for the management of diabetes mellitus with GLI, in general the dosage of GLI should be lowest which is sufficient to achieve the desired metabolic control. Starting dose : 1-2mg OD Maintenance :1-4mg OD Maximum recommended dose : 8mg OD

Contra-Indication Hypersensitivity to glimepiride other sulphonyl urea.

Drug Interactions With NSAIDs like Salicylates, Sulphoamides, Chlorampenizol coumarin and probencid may potentiate the hypoglycaemic action of glimepride. Thiazides, other diuretic, phothiazides, thyroid products, oral contraceptives, phenytoin tend to produce hyperglycaemic.

Special Precautions In the initial weeks of treatment the risk of hypoglycaemia, may be increased and necessities especially careful monitoring.

Adverse Effects GI disturbance, rarely thrombopaenia , leucopaenia, haemolytic anaemia, occasionally allergic.

© Medic8 ® All Rights Reserved.